SAB Biotherapeutics Statistics Share Statistics SAB Biotherapeutics has 9.29M
shares outstanding. The number of shares has increased by -99.14%
in one year.
Shares Outstanding 9.29M Shares Change (YoY) -99.14% Shares Change (QoQ) 0% Owned by Institutions (%) 9.5% Shares Floating 7.49M Failed to Deliver (FTD) Shares 290 FTD / Avg. Volume 1.38%
Short Selling Information The latest short interest is 13.46K, so 0% of the outstanding
shares have been sold short.
Short Interest 13.46K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 8.9
Valuation Ratios The PE ratio is -1.03 and the forward
PE ratio is null.
SAB Biotherapeutics's PEG ratio is
0.02.
PE Ratio -1.03 Forward PE n/a PS Ratio 26.54 Forward PS 0.6 PB Ratio 1.35 P/FCF Ratio -1.01 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.98,
with a Debt / Equity ratio of 0.18.
Current Ratio 2.98 Quick Ratio 2.98 Debt / Equity 0.18 Debt / EBITDA -0.16 Debt / FCF -0.13 Interest Coverage -134.77
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $20.99K Profits Per Employee $-541.35K Employee Count 63 Asset Turnover 0.03 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 37.46% in the
last 52 weeks. The beta is 0.55, so SAB Biotherapeutics's
price volatility has been higher than the market average.
Beta 0.55 52-Week Price Change 37.46% 50-Day Moving Average 0.03 200-Day Moving Average 0.05 Relative Strength Index (RSI) 61.26 Average Volume (20 Days) 20,980
Income Statement In the last 12 months, SAB Biotherapeutics had revenue of 1.32M
and earned -34.11M
in profits. Earnings per share was -3.68.
Revenue 1.32M Gross Profit -3.47M Operating Income -42.91M Net Income -34.11M EBITDA -28.99M EBIT -33.79M Earnings Per Share (EPS) -3.68
Full Income Statement Balance Sheet The company has 8.9M in cash and 4.67M in
debt, giving a net cash position of 4.23M.
Cash & Cash Equivalents 8.9M Total Debt 4.67M Net Cash 4.23M Retained Earnings -124.17M Total Assets 38.12M Working Capital 6.64M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -34.29M
and capital expenditures -337.26K, giving a free cash flow of -34.63M.
Operating Cash Flow -34.29M Capital Expenditures -337.26K Free Cash Flow -34.63M FCF Per Share -3.74
Full Cash Flow Statement Margins Gross margin is -262.41%, with operating and profit margins of -3244.87% and -2579.03%.
Gross Margin -262.41% Operating Margin -3244.87% Pretax Margin -2579.03% Profit Margin -2579.03% EBITDA Margin -2192.54% EBIT Margin -3244.87% FCF Margin -2618.65%
